News

06/30/2023 IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the company’s management team will participate at the SVB Securities Therapeutics Forum. SVB Securities Therapeutics ForumDate: Tuesday, July…

October 6, 2023 IRVINE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate in the Jefferies Biotech CNS/Neuro Summit. Jefferies Biotech CNS/Neuro SummitDate:…

November 2, 2023 IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate in the following investor conferences. Jefferies London Healthcare ConferenceDate: Tuesday,…

August 29, 2023 IRVINE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate at the upcoming healthcare investor conferences. Citi BioPharma ConferenceDate: Wednesday,…

Leriglitazone was well tolerated, and significant benefit was shown through clinically meaningful myelopathy endpoints and reduced progression of cerebral lesions Mataró, Barcelona, Spain, January 20, 2023 – Minoryx Therapeutics (“Minoryx”), a Phase 3 clinical stage biotech company focused on the development of differentiating treatment options in orphan central nervous system (CNS) disorders, today announces that data from its Phase 2/3…

05/31/2023 IRVINE, Calif., May 31, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate at the Jefferies Healthcare Conference. Jefferies Healthcare ConferenceDate: Wednesday, June 7, 2023Location:…